Anthropic acquires Coefficient Bio in reported $400M biotech deal

Anthropic has completed the acquisition of stealth biotech startup Coefficient Bio in a stock transaction reportedly valued at around $400 million, according to reports from The Information and journalist Eric Newcomer. Sources familiar with the matter confirmed that the deal has been finalised, although they declined to verify the exact financial terms.

The acquisition marks a continued expansion of Anthropic’s ambitions in the healthcare and life sciences sectors. This follows the company’s earlier October announcement of its “Claude for Life Sciences” initiative, a platform designed to help researchers accelerate scientific discovery through advanced AI tools.

Coefficient Bio was founded just eight months ago by Samuel Stanton and Nathan C. Frey. Before launching the startup, both founders were involved in computational drug discovery work at Genentech’s Prescient Design division. Their experience applying machine learning techniques to biological problems helped shape the company’s focus on improving efficiency in drug discovery and broader biological research.

The startup had been developing AI-driven approaches to streamline complex research workflows, particularly in areas where traditional methods are time-consuming and resource-intensive. By leveraging artificial intelligence, Coefficient Bio sought to enhance the speed and accuracy of identifying potential drug candidates and analysing biological data.

As part of the acquisition, Coefficient Bio’s team — which consists of approximately 10 members — is expected to be integrated into Anthropic’s existing health and life sciences division. This move is likely to strengthen Anthropic’s capabilities in applying AI to real-world scientific challenges, particularly in biotechnology and pharmaceutical research.

The deal reflects a growing trend among major AI companies to move beyond general-purpose models and into specialised domains such as healthcare, where the potential impact — and commercial opportunity — is significant. By bringing in a focused team with deep expertise in computational biology, Anthropic is positioning itself to play a more direct role in advancing AI-driven innovation in medicine and life sciences.